Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more